Skip to main content

Morning Bell 12 November

Bell Direct
November 12, 2025

In the US, Wall St saw a mixed session overnight, with the Dow Jones closing up 1.18% to set a fresh record high, while the Nasdaq slipped 0.25% as volatility in the AI sector continues. Nvidia pulled back 2% from yesterday’s rally on news that Japanese investment holding company SoftBank had sold its entire 5.8 billion USD stake in the company. Meanwhile, the S&P 500 also saw gains overnight, adding 0.21%.

In Europe, markets across the continent carried their momentum from yesterday as optimism following the end of the US government shutdown continued. The pan European Stoxx 600 index closed up 1.3%, as the FTSE and French CAC saw gains of over 1%, while the German DAX was slightly behind, only advancing half a percent.

Back home yesterday, despite opening in the green and seeing 8 of the 11 key sectors positive, the ASX 200 declined 0.2% on the day. It was primarily weighed down by the financial sector, where the big story was Commonwealth Bank (ASX:CBA) shares tumbling 6.6%, after the bank reported higher net interest margin and cost pressure than expected.

What to watch today:

  • Looking ahead to today’s trading session, the SPI futures indicate that the ASX will open up 0.2%.
  • Both gold and silver have continued to rally, bringing them now to a 5% and 8.5% advance on the week so far respectively. Gold is currently trading at 4129USD per ounce, while silver is at 51USD per ounce.
  • Crude oil is trading 1.5% higher at nearly 61 USD per barrel, as the US recently announced fresh sanctions on Russian oil along with optimism on the impending end of the government shutdown.
  • Iron ore is down 0.4% at 103 UD and 56 cents per tonne.

Trading ideas:

  • Bell Potter has upgraded its recommendation on pharmaceutical giant Pro Medicus (ASX:PME) from a hold to a buy, with a 12 month target price of $320 per share, based on its baseline revenue forecast along with the announcement of 3 new major deals in the US.
  • And Trading Central have identified a bullish signal in pathology services provider Australian Clinical Labs (ASX:ACL), indicating that the price may rise from the close of $2.64 to the range of $2.99 to $3.07 over a period of 12 days, according to the standard principles of technical analysis.

Market Update

Julia Lee
March 8, 2017

Market Update

Julia Lee
March 6, 2017

Market Update 3 March

Julia Lee
March 3, 2017

Market Update

Julia Lee
March 2, 2017

How to create a watchscreen

Bell Direct
March 1, 2017

How to set trading alerts

Bell Direct
March 1, 2017

How to transfer your shares to Bell Direct

Bell Direct
February 27, 2017

How to get a stock quote

Bell Direct
February 27, 2017

February newsletter Julia’s insights

Julia Lee
February 24, 2017

CEO interview – Cobalt Blue

Bell Direct
February 21, 2017

Your Money Your Call

Julia Lee
February 14, 2017